Related Experiment Video

Updated: Mar 1, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Once-Weekly Lonapegsomatropin Was Efficacious and Well Tolerated in Chinese Children with Growth Hormone Deficiency:

Yanqin Ying1, Haiyan Wei2, Yan Zhong3

  • 1Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Hormone Research in Paediatrics
|February 27, 2026
PubMed

Insights

Weekly lonapegsomatropin showed superior efficacy compared to daily somatropin in treating Chinese children with growth hormone deficiency (GHD). Both treatments were found to be safe and well-tolerated, offering a new therapeutic option.

Area of Science:

  • Pediatric Endocrinology
  • Pharmacology
  • Clinical Trials

Background:

  • Lonapegsomatropin is an approved once-weekly treatment for pediatric growth hormone deficiency (GHD).
  • This study is the first to compare weekly lonapegsomatropin with daily somatropin in treatment-naive Chinese children with GHD.

Purpose of the Study:

  • To assess the efficacy and safety of weekly lonapegsomatropin versus daily somatropin in Chinese children with GHD.
  • To evaluate lonapegsomatropin's non-inferiority and superiority in improving growth parameters.

Main Methods:

  • A 52-week, randomized, open-label, active-controlled Phase 3 trial (briGHt trial) in China.
  • 153 treatment-naive, prepubertal children with GHD were randomized to weekly lonapegsomatropin or daily somatropin.
  • Primary endpoint: annualized height velocity (AHV) at week 52; Secondary endpoints: change in height SDS, IGF-1, and safety.

Main Results:

  • Weekly lonapegsomatropin demonstrated non-inferiority and superiority over daily somatropin, with a significantly higher AHV (10.66 cm/year vs. 9.75 cm/year, p=0.0010).
  • Lonapegsomatropin also showed a greater improvement in height SDS from week 13 onwards (p < 0.05).
  • Safety profiles were comparable between the two treatment groups.

Conclusions:

  • Weekly lonapegsomatropin is non-inferior and superior in efficacy to daily somatropin for treating naive Chinese children with GHD.
  • Lonapegsomatropin offers a comparable safety and tolerability profile to daily somatropin.
  • Weekly lonapegsomatropin presents a promising alternative treatment for pediatric GHD.
Abstract

Keywords:
Chinese childrenGrowth hormone deficiencyLonapegsomatropinLong-acting growth hormone therapySuperiorityTransCon hGH

More Related Videos

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays11:17

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays

Published on: January 7, 2016

17.2K
Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects07:53

Peptides from Phage Display Library Modulate Gene Expression in Mesenchymal Cells and Potentiate Osteogenesis in Unicortical Bone Defects

Published on: December 10, 2010

18.6K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
293
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
338
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
387
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
392
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
192